GigaGen

GigaGen is pioneering a novel class of recombinant polyclonal antibody drugs using its industry-leading single-cell technology platforms. Its pipeline includes a Phase 1 anti-CTLA-4 monoclonal antibody (GIGA-564) for oncology and a Phase 1 recombinant polyclonal (GIGA-2339) for Hepatitis B, alongside significant biodefense contracts. As a Grifols subsidiary, the company combines innovative discovery capabilities with the resources and manufacturing expertise of a global plasma leader, positioning it to advance potent, engineered antibody therapies for complex diseases.

Proprietary single-cell genomics platforms that capture and sequence complete antibody repertoires from human B cells. This enables the discovery of novel monoclonal antibodies and the engineering of recombinant polyclonal antibody drugs—defined mixtures of hundreds to thousands of antibodies manufactured consistently in cell culture.

In monoclonal discovery, GigaGen competes with numerous biotechs using phage display, B-cell sorting, and other single-cell methods. Its key differentiation is the scale and depth of repertoire analysis. In polyclonals, it is a first-mover against plasma-derived products from Grifols, Takeda, and CSL, and must compete on cost and clinical differentiation. In biodefense, it competes for government contracts with other antibody developers.